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ABSTRACT: Protein flexibility poses a major challenge in binding site
identification. Several computational pocket detection methods that
utilize small-molecule probes in molecular dynamics (MD) simulations
have been developed to address this issue. Although they have proven
hugely successful at reproducing experimental structural data, their ability
to predict new binding sites that are yet to be identified and characterized
has not been demonstrated. Here, we report the use of benzenes as probe
molecules in ligand-mapping MD (LMMD) simulations to predict the
existence of two novel binding sites on the surface of the oncoprotein
MDM2. One of them was serendipitously confirmed by biophysical
assays and X-ray crystallography to be important for the binding of a new
family of hydrocarbon stapled peptides that were specifically designed to target the other putative site. These results highlight the
predictive power of LMMD and suggest that predictions derived from LMMD simulations can serve as a reliable basis for the
identification of novel ligand binding sites in structure-based drug design.
The identification and characterization of binding pockets isan important component of structure-based drug design.
It is also often the first step in evaluating the druggability of a
protein target.1,2 In recent decades, various computational
algorithms and methods that rely on the use of static protein
structures have been developed for rapid identification of
binding pockets for ligand design.1 They are, however, severely
limited by their dependence on available protein structures.
Proteins are intrinsically flexible and frequently undergo
conformational changes on ligand binding.3−6 A major concern
is that cryptic binding pockets that are absent in the input
structures and present themselves only in the presence of a
suitable interacting ligand will be missed. This is often the case
for hydrophobic pockets, which tend to remain occluded in
polar solvents and open up only in the presence of less polar
ligands.7
To address this issue, there have been recent efforts to
develop molecular dynamics (MD)-based methods that
incorporate small molecules into the protein’s solvent box for
pocket detection.8−12 In these simulations, the probes interact
dynamically with the protein surface, allowing for ligand-
induced conformational changes. The use of hydrophobic
probes is of particular interest because it reduces the solvent
polarity, thus facilitating the opening and enlargement of
hydrophobic pockets that may otherwise remain undetected in
pure water simulations of the protein.7 Ligand-mapping MD
(LMMD)13,14 is one of two probe-based MD simulation
methods that employ hydrophobic probes for pocket detection.
In contrast to the related site identification by ligand
competitive saturation (SILCS) method,9 LMMD does not
require the addition of artificial interligand repulsive energy
terms because of the use of relatively low concentrations of
hydrophobic probes to avoid ligand aggregation. LMMD
simulations have been shown to be especially useful at revealing
cryptic binding sites14 and were previously used to guide the
design of a ligand to target a cryptic pocket.13 Recently, LMMD
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has also been established as a reliable method for the
identification of hydrophobic peptide binding sites.15 To date,
probe-based MD simulations have mostly been limited to the
reproduction of known structural data. Unlike the non MD-
based pocket detection methods,16 there have been no previous
reports of the successful prediction of a previously unknown
binding site by these simulations, although a recent study
suggests that SILCS has the potential to propose alternative
binding sites.17 A demonstration of the predictive power of
probe-based MD simulations will provide confidence for and
encourage their application in structure-based drug design
projects. Here, we focus on the promising anticancer
therapeutic target MDM2 as a prototypical example for the
detection of novel ligand binding sites by LMMD.
The E3 ubiquitin ligase MDM2 is a potent inhibitor of the
tumor suppressor protein p53,18 which plays an essential role in
coordinating cellular responses, including cell cycle arrest,
apoptosis, and senescence, to a variety of stress signals.19
MDM2 binds to the transactivation domain of p53 to block
p53-mediated transactivation20 and targets it for ubiquitin-
mediated proteolysis.21 It is overexpressed in many cancers and
is thought to be one of the primary causes of p53 network
inactivation in p53 wild-type (WT) tumors.22 Antagonists of
the MDM2−p53 interaction can reactivate the p53 response,
leading to cell cycle arrest and apoptosis in tumor cells.23,24
Several small-molecule inhibitors of the MDM2−p53 inter-
action have been developed, and some of them have reached
clinical trials.25,26 These molecules mimic the three key binding
residues (Phe19, Trp23, and Leu26) in the p53 transactivation
domain, which binds as an amphipathic α-helix to a deep
hydrophobic cleft in the N-terminal domain of MDM2.27
Besides small molecules, peptides derived from the trans-
activation domain of p53 have also been used to inhibit the
MDM2−p53 interaction. Unlike small molecules, however,
linear peptides are susceptible to proteolytic cleavage, lack a
well-defined conformation prior to target engagement, and are
poorly cell-permeable.28 These shortcomings can potentially be
overcome by hydrocarbon stapling, in which two unnatural
residues bearing olefin side chains of varying lengths are
introduced into the α-helix of the peptide, followed by a
ruthenium-catalyzed ring-closing metathesis reaction to form a
covalent staple across one or two α-helical turns.29 Hydro-
carbon stapling generally leads to enhanced helicity, protease
resistance, and cell permeability.30,31 Three families of MDM2-
binding hydrocarbon stapled peptides have been identified to
date: one derived from the WT p53 sequence32 and two others
from phage display studies.33,34 Two of these peptides have
been cocrystallized with MDM2, revealing that the hydro-
carbon staple also interacts with the protein surface, thus
augmenting the hydrophobic interactions at the binding
interface.35,36
In this Letter, we describe the use of LMMD to identify two
new binding sites close to the consensus p53-binding cleft in
MDM2. Subsequent biophysical and crystallographic studies
showed that one of these sites is important for the binding of a
novel set of hydrocarbon stapled peptides.
The crystal structure of human MDM2 in complex with the
p53 transactivation domain peptide (PDB code 1YCR)27 was
used as the initial structure for the LMMD simulations. As
cryptic binding sites tend to be hydrophobic in nature,7
benzene was chosen as the mapping ligand to better explore
such sites. An initial set of 10 independent 5 ns LMMD
simulations with different starting benzene distributions was
performed on apo MDM2 after removing p53 from the
complex structure. A relatively low benzene concentration (0.2
M) was used to prevent phase separation and ligand
aggregation on the protein surface, which may cause
denaturation.37 A second set of LMMD simulations was
performed on p53-bound MDM2 to determine whether the
binding sites that are discrete from the p53-binding cleft could
be reproduced in the presence of the peptide.
Analysis of the benzene occupancy maps generated from the
apo and holo LMMD simulations revealed two putative discrete
binding sites close to the p53-binding cleft, which have never
been exploited by any known inhibitors of MDM2 and may be
utilized to improve the affinity and selectivity of existing
Figure 1. Putative binding sites (blue circles) identified on the MDM2 surface (white). (A) Benzene occupancy maps (black mesh) overlaid on the
structure of MDM2 complexed with nutlin-2 (PDB code 1RV1), showing detection of the second nutlin interaction site. The neighboring protomer
is represented as white cartoon. (B) Residues forming the second nutlin interaction site. (C) Benzene occupancy maps overlaid on the structure of
MDM2 complexed with p53 peptide (PDB code 1YCR), showing detection of the proximal P27 binding site. (D) Residues forming the proximal
P27 binding site.
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ligands. The first binding site lies between Tyr100 and Tyr104
and was mapped by the benzene probes in both apo and holo
LMMD simulations. It was found to correspond to a crystal
packing contact for a second nutlin molecule in the crystal
structure of its complex with MDM2 (Figure 1A).38 This
secondary nutlin interaction site is defined by seven residues:
Val28, Met50, Tyr100, Ile103, Tyr104, Leu107, and Val109
(Figure 1B). These residues potentially constitute a cryptic
binding pocket that is occluded by Tyr104 in the majority of
MDM2 structures, including the one used for the LMMD
simulations. There is experimental evidence to suggest that the
region around this cryptic site may be relevant for nutlin
binding at the p53-binding cleft;39 however, its ability to bind
ligands has not been verified.
The second putative binding site was identified in the apo
LMMD simulations within a region contiguous to where Pro27
of p53 binds (Figure 1C); however, it was not detected in the
corresponding holo simulations because it was occluded by the
C-terminal region of the p53 peptide. This “proximal P27 site”
is essentially a relatively shallow hydrophobic basin constituted
by Thr26, Met50, Lys51, Leu54, Tyr100, and Tyr104 (Figure
1D).
The proximity of the second nutlin interaction site to the
p53-binding cleft raises the possibility of accessing it by
extension of the p53 peptide. Suitable MDM2 structures, in
which the identified cryptic pocket was present, were selected
from the apo and holo LMMD simulations. The p53 peptide
was modeled onto the apo MDM2 structure by extraction from
the 1YCR crystal structure. Either a phenylalanine or a tyrosine
residue was then appended to the peptide’s C-terminus, such
that there was optimal overlap of the phenyl ring with the
benzene molecule bound at the second nutlin interaction site
(Figure 2A). The peptide in the holo MDM2 structure was
similarly extended. We then replaced the WT p53 sequence in
these extended peptides with that of a previously reported
potent MDM2-binding and p53-activating stapled peptide,
sMTide-02.33 The i, i + 7 staple used in sMTide-02, however,
could not be transferred to these peptides because it would
induce an additional helical turn that prevents the appended
residue from accessing the second nutlin interaction site.
Instead, a shorter i, i + 4 staple formed by two (R)-2-(4′-
pentenyl)alanine residues (R5) was used to maintain the
extended structure of the C-terminal residues. The R,R
configuration of the hydrocarbon staple was preferred to the
more common S,S configuration because it allows the staple to
point toward and form intimate hydrophobic contacts with the
MDM2 surface. These novel stapled peptides were termed YS-1
(TSFR5EYWR5LLPENF) and YS-2 (TSFR5EYWR5LLPENY),
respectively.
MD simulations of the complexes of MDM2 with WT p53,
sMTide-02, YS-1, and YS-2 were performed for 50 ns each to
evaluate their stability. The structures of YS-1 and YS-2 did not
deviate significantly from their initial minimized structures, with
root-mean-square deviation (RMSD) values remaining below
1.6 Å (Figure S1). The Phe (Figure 2B) and Tyr extensions
(not shown) remained bound at their targeted binding sites at
the end of the simulations, indicating the stability of the
predicted binding mode. Binding free energies of the various
MDM2−peptide complexes were then estimated using the
molecular mechanics/generalized Born surface area (MM/
GBSA) method.40 The sMTide-02 peptide was predicted to
have a higher binding affinity for MDM2 compared to WT p53
peptide (Table S5), in agreement with previous experimental
results.33 Notably, the calculations suggest that both YS-1 and
YS-2 are significantly more potent binders of MDM2 than
sMTide-02 (Table S5). To validate the computational
predictions, the stapled peptides were subsequently charac-
terized in biophysical and X-ray crystallographic experiments.
Binding affinities of the stapled peptides for MDM2 were
determined in competitive fluorescence polarization (FP)
assays (Table 1). The designed stapled peptides exhibited
approximately up to 5-fold improvement in binding potency
relative to sMTide-02, in qualitative agreement with the
computational predictions. Incorporation of a tyrosine instead
of phenylalanine at the C-terminus of the stapled peptides
made little difference to their binding affinities.
Crystal structures of the N-terminal domain of MDM2 in
complex with YS-1 and YS-2 were solved to elucidate their
binding modes. The two peptides bind to MDM2 very
similarly, with only minor variations for some solvent-exposed
residues (Figure 3A and Figure S3). Both stapled peptides
adopt an α-helical structure with Phe19, Trp23, and Leu26
Figure 2. Design of extended stapled peptides. (A) A Phe residue
(green) was appended to the C-terminus of the WT p53 peptide
(PDB code 1YCR) such that it overlapped with the benzene molecule
(orange) bound in the second nutlin interaction site. (B)
Conformation of YS-1 after 50 ns of MD simulation.
Table 1. Dissociation Constants (Kd) of Stapled Peptides As
Determined by Competitive Fluorescence Polarization
Titrations
peptide sequence Kd (nM)
sMTide-02 Ac-17TSFR8EYWALLS5
27-NH2 34.4 ± 2.0
YS-1 Ac-17TSFR5EYWR5LLPENF
30-NH2 9.9 ± 1.5
YS-2 Ac-17TSFR5EYWR5LLPENY
30-NH2 7.4 ± 1.5
YS-3 Ac-17TSFR5EYWR5LLPEN
29−NH2 36.1 ± 2.9
YS-4 Ac-17TSFR5EYWR5LLPENA
30-NH2 27.7 ± 1.3
YS-5 Ac-17TSFR5EYWR5LLSENF
30-NH2 11.6 ± 0.9
YS-6 Ac-17TSFR5EYWR5LLSENY
30-NH2 8.8 ± 0.6
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bound in their consensus pockets. The i, i + 4 hydrocarbon
staple packs snugly against the MDM2 glycine shelf in a
manner broadly similar to that seen for longer i, i + 7 staples of
other MDM2-binding stapled peptides.35,36
Surprisingly, the last three residues of YS-1 and YS-2 do not
adopt the linear conformation observed at the C-terminus of
WT p53 when bound to MDM2; instead they extend the
helical fold to create a kinked helix encompassing residues 19−
30 (Figure 4A, residue numbers follow that in WT p53
sequence). While Pro27 acts as a helix breaker in the p53
peptide because of steric constraints and its inability to
maintain the backbone hydrogen bonding network, it is
unexpectedly incorporated into the helices of YS-1 and YS-2,
allowing it to form close hydrophobic contacts with the MDM2
surface. It is likely that this is driven by the presence of the
hydrocarbon staple, which has the ability to stabilize α-helices
beyond the stapled α-helical turn.41 This results in the C-
termini of the peptides packing into the cleft between helices
α3 and α5 (Figure 3B), with Phe/Tyr30 bound at the proximal
P27 site instead of the second nutlin binding site (Figure S5),
contrary to the computational models. The presence of a
proline in an α-helix is strongly linked to helix kinking,42 similar
to what is observed here. A recent survey of the Protein Data
Bank (PDB)43 reveals that this phenomenon is commonly
found in long α-helices, occurring in 30% of membrane protein
helices and 20% of length-matched (≥20 residues) globular
protein helices.44 Tyr100 and Tyr104, which line the proximal
P27 site, are both rotated toward the peptide, relative to the
WT p53-MDM2 complex structure (Figure 3B). Tyr100 forms
an edge-to-face interaction with Phe/Tyr30 and a hydrogen
bond with the backbone carbonyl of Leu26 from the peptides,
while rotation of Tyr104 allows it to form a hydrogen bond
with the hydroxyl of Tyr30 and slightly occlude the putative
second nutlin binding site.
The binding of the N-termini of YS-1 and YS-2 (residues
17−23) is very similar to that of two other MDM2-binding
stapled peptides, SAH-p53-8 and M06 (Figure 4B). However,
the different stapling strategies resulted in residues 24−28
being bound in a slightly different manner. The introduction of
the second stapling point at residue 24 of YS-1 and YS-2 causes
Leu25 and Leu26 to be displaced further along the helical axis.
This results in a more expanded helical structure with a 1.7 Å
displacement at the Cα position of Leu26 (compared to SAH-
p53-8), which forces Leu26 into a position and conformation
that is midway between that of SAH-p53-8/M06 and WT p53.
Residues 27−29 then adopt a tighter helical conformation than
in SAH-p53-8, bringing Asn29 of SAH-p53-8 and Gln29 in YS-
1 and YS-2 closer together.
MD simulations show that this unexpected binding mode of
the stapled peptides is stable (Figure S6). Although MM/GBSA
analysis suggests that adoption of the crystallographic binding
mode results in a loss of binding free energy compared to the
predicted binding mode, YS-1 and YS-2 were predicted to be
tighter MDM2 binders than sMTide-02 (Table S5), in
agreement with the FP assay results. The unanticipated binding
modes of the stapled peptides observed in the crystal structures
highlight the challenges in characterizing multiple conforma-
tional states with their distinct thermodynamic profiles.45 Fine
balances between enthalpic and entropic contributions often
make it difficult to predict the behavior of the protein and its
ligand upon complex formation.46
The effect of Phe/Tyr30 on the interaction with MDM2 was
further investigated by synthesizing two control stapled
peptides, one lacking the C-terminal aromatic residue (YS-3)
and the other having alanine as the C-terminal residue (YS-4),
and then evaluating their binding affinities in competitive FP
binding assays. The dissociation constants (Kd) of YS-3 and YS-
4 were 5-fold and 4-fold higher than that of YS-2, respectively.
Figure 3. Crystal structures of MDM2 (green with translucent surface)
bound to YS-1 and YS-2 (PDB codes 4UE1 and 4UD7, respectively).
(A) MDM2 bound to YS-1 (yellow) with YS-2 (orange) super-
imposed. (B) Interactions of Tyr30 within the proximal P27 site, with
hydrogen bonds represented as dashed lines.
Figure 4. Comparison of YS-2 (orange) to (A) WT p53 (yellow, PDB
code 1YCR), (B) M06 (magenta, PDB code 4UMN) and SAH-p53-8
(cyan, PDB code 3V3B).
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The slightly lower Kd of YS-4 compared to YS-3 could be due
to the weak hydrophobic interaction of the methyl side chain of
Ala30 with the proximal P27 site. Together with the crystal
structures of MDM2 bound to YS-1 and YS-2, these results
suggest that the proximal P27 site is a functional binding site
that plays an important role in ligand binding to MDM2.
The secondary structures of unbound YS-1 and YS-2 were
characterized by circular dichroism spectroscopy. Both peptides
show very low overall α-helicity as compared to sMTide-02,
based on their molar circular dichroism value at 222 nm (Figure
S7). To increase the α-helicity of the designed peptides, we
replaced Pro27 in YS-1 and YS-2 with a serine residue,
generating the respective analogs YS-5 and YS-6. As predicted,
YS-5 and YS-6 exhibited a marked increase in α-helicity relative
to YS-1 and YS-2 (Figure S7). However, enhancing peptide α-
helicity did not improve the binding affinity (Table 1). This
could be due to the loss of favorable hydrophobic interactions
of Pro27 with the MDM2 surface when it is replaced by serine,
which negates the reduced entropic cost of increasing α-
helicity.
In this proof-of-concept study, we have used a probe-based
MD method called LMMD to detect novel binding sites on the
surface of the anticancer protein target MDM2. Two adjacent
putative binding sites on the N-terminal domain of MDM2
close to the p53 binding pocket were identified. Through
biophysical binding assays and X-ray crystallography, we
serendipitously confirmed the proximal P27 site as a functional
ligand binding site by using hydrocarbon stapled peptides that
were designed to target the downstream putative site. We
measured a 5-fold improvement in binding affinity for stapled
peptides that interact with the proximal P27 binding site (YS-2
versus YS-3, Table 1). Because of its proximity to the p53-
binding cleft, it may be exploited to enhance the binding
potencies of current MDM2 ligands. Further optimization of
inhibitor structure, such as the use of alternative staple
architectures47 and replacement of Pro27 with helix-stabilizing
aliphatic residues that retain hydrophobic interactions with the
MDM2 surface, may also result in binding affinity improve-
ments greater than those observed here.
Here, we also present the first ever crystal structures of an i, i
+ 4 (R,R) stapled peptide bound to its protein target. The
structures of these complexes reveal the rare and unusual
incorporation of a proline residue into the α-helix of the stapled
peptides. This implies that the hydrocarbon staple is able to
exert a strong helix stabilization effect that extends to residues
beyond the staple, including those with low α-helix propensities
such as proline. We also report four modified stapled peptides
with MDM2 binding affinities superior to that of the parent
peptide sMTide-02, indicating their potential as templates for
the development of a new family of potent p53-activating
stapled peptides. Studies are now underway to evaluate their
biological activities and develop variants with enhanced
potencies.
We have used LMMD simulations to identify a novel binding
site on the N-terminal domain of MDM2 close to the p53-
binding cleft. The work described here is a significant step
forward for the emerging field of probe-based MD because to
the best of our knowledge, this is the first study to utilize such
simulations to successfully predict and subsequently validate
with definitive biophysical and structural data a previously
unknown binding site. The results obtained corroborate the use
of probe-based MD techniques to identify novel binding sites
and inform structure-based drug design.
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